• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于疫苗开发的工程衍生纳米颗粒

Engineering -Derived Nanoparticles for Vaccine Development.

作者信息

Tang Shubing, Zhao Chen, Zhu Xianchao

机构信息

Shanghai Reinovax Biologics Co., Ltd., Pudong New District, Shanghai 200135, China.

Shanghai Public Health Clinical Center, Fudan University, Shanghai 201058, China.

出版信息

Vaccines (Basel). 2024 Nov 18;12(11):1287. doi: 10.3390/vaccines12111287.

DOI:10.3390/vaccines12111287
PMID:39591189
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11598912/
Abstract

The development of effective vaccines necessitates a delicate balance between maximizing immunogenicity and minimizing safety concerns. Subunit vaccines, while generally considered safe, often fail to elicit robust and durable immune responses. Nanotechnology presents a promising approach to address this dilemma, enabling subunit antigens to mimic critical aspects of native pathogens, such as nanoscale dimensions, geometry, and highly repetitive antigen display. Various expression systems, including (), yeast, baculovirus/insect cells, and Chinese hamster ovary (CHO) cells, have been explored for the production of nanoparticle vaccines. Among these, stands out due to its cost-effectiveness, scalability, rapid production cycle, and high yields. However, the manufacturing platform faces challenges related to its unfavorable redox environment for disulfide bond formation, lack of post-translational modifications, and difficulties in achieving proper protein folding. This review focuses on molecular and protein engineering strategies to enhance protein solubility in and facilitate the in vitro reassembly of virus-like particles (VLPs). We also discuss approaches for antigen display on nanocarrier surfaces and methods to stabilize these carriers. These bioengineering approaches, in combination with advanced nanocarrier design, hold significant potential for developing highly effective and affordable -derived nanovaccines, paving the way for improved protection against a wide range of infectious diseases.

摘要

有效疫苗的研发需要在最大化免疫原性和最小化安全问题之间取得微妙的平衡。亚单位疫苗虽然通常被认为是安全的,但往往无法引发强大而持久的免疫反应。纳米技术提供了一种有前景的方法来解决这一困境,使亚单位抗原能够模拟天然病原体的关键特征,如纳米级尺寸、几何形状和高度重复的抗原展示。人们已经探索了各种表达系统,包括()、酵母、杆状病毒/昆虫细胞和中国仓鼠卵巢(CHO)细胞,用于生产纳米颗粒疫苗。其中,()因其成本效益、可扩展性、快速生产周期和高产量而脱颖而出。然而,()制造平台面临着与二硫键形成的不利氧化还原环境、缺乏翻译后修饰以及实现正确蛋白质折叠的困难相关的挑战。本综述重点关注分子和蛋白质工程策略,以提高蛋白质在()中的溶解度,并促进病毒样颗粒(VLP)的体外重新组装。我们还讨论了在纳米载体表面展示抗原的方法以及稳定这些载体的方法。这些生物工程方法与先进的纳米载体设计相结合,在开发高效且经济实惠的()衍生纳米疫苗方面具有巨大潜力,为改善对多种传染病的防护铺平了道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/11598912/65a98a930343/vaccines-12-01287-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/11598912/51d742fb7bf1/vaccines-12-01287-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/11598912/ac92e7751233/vaccines-12-01287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/11598912/dacb4b7096a0/vaccines-12-01287-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/11598912/62bb450f0e9b/vaccines-12-01287-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/11598912/65a98a930343/vaccines-12-01287-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/11598912/51d742fb7bf1/vaccines-12-01287-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/11598912/ac92e7751233/vaccines-12-01287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/11598912/dacb4b7096a0/vaccines-12-01287-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/11598912/62bb450f0e9b/vaccines-12-01287-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/11598912/65a98a930343/vaccines-12-01287-g004.jpg

相似文献

1
Engineering -Derived Nanoparticles for Vaccine Development.用于疫苗开发的工程衍生纳米颗粒
Vaccines (Basel). 2024 Nov 18;12(11):1287. doi: 10.3390/vaccines12111287.
2
Optimized production of full-length PCV2d virus-like particles in Escherichia coli: A cost-effective and high-yield approach for potential vaccine antigen development.优化大肠杆菌中全长 PCV2d 病毒样颗粒的生产:一种具有成本效益和高产量的潜在疫苗抗原开发方法。
Microb Pathog. 2024 May;190:106630. doi: 10.1016/j.micpath.2024.106630. Epub 2024 Mar 29.
3
Development of a Gold Nanoparticle Vaccine against Enterohemorrhagic Escherichia coli O157:H7.开发一种针对肠出血性大肠杆菌 O157:H7 的金纳米颗粒疫苗。
mBio. 2019 Aug 13;10(4):e01869-19. doi: 10.1128/mBio.01869-19.
4
Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.嵌合乙型肝炎核心病毒样颗粒携带 SARS-CoV2 表位可在小鼠中引发体液免疫应答。
Microb Cell Fact. 2023 Feb 25;22(1):39. doi: 10.1186/s12934-023-02043-z.
5
Integrated molecular and bioprocess engineering for bacterially produced immunogenic modular virus-like particle vaccine displaying 18 kDa rotavirus antigen.用于细菌生产展示18 kDa轮状病毒抗原的免疫原性模块化病毒样颗粒疫苗的整合分子与生物过程工程
Biotechnol Bioeng. 2017 Feb;114(2):397-406. doi: 10.1002/bit.26068. Epub 2016 Aug 17.
6
Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells.在中国仓鼠卵巢细胞中生产的可制造性严重急性呼吸综合征冠状病毒2刺突病毒样颗粒的临床前评估。
Commun Med (Lond). 2023 Aug 23;3(1):116. doi: 10.1038/s43856-023-00340-7.
7
Self-assembling protein nanoparticles and virus like particles correctly display β-barrel from meningococcal factor H-binding protein through genetic fusion.自组装蛋白纳米颗粒和类病毒颗粒通过基因融合正确展示脑膜炎奈瑟菌因子 H 结合蛋白的β-桶状结构。
PLoS One. 2022 Sep 16;17(9):e0273322. doi: 10.1371/journal.pone.0273322. eCollection 2022.
8
Advancements in protein nanoparticle vaccine platforms to combat infectious disease.蛋白质纳米颗粒疫苗平台在传染病防治方面的进展。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 May;13(3):e1681. doi: 10.1002/wnan.1681. Epub 2020 Nov 8.
9
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies.基于蛋白质的疫苗生产平台:从经典到下一代策略。
Biomolecules. 2021 Jul 21;11(8):1072. doi: 10.3390/biom11081072.
10
derived virus-like particles in vaccine development.疫苗研发中衍生的病毒样颗粒。
NPJ Vaccines. 2017 Feb 9;2:3. doi: 10.1038/s41541-017-0006-8. eCollection 2017.

引用本文的文献

1
Innovation in mRNA Vaccines and RNAi via Protein Nanocages.通过蛋白质纳米笼实现的信使核糖核酸疫苗和RNA干扰技术的创新。
Vaccines (Basel). 2025 Jun 18;13(6):653. doi: 10.3390/vaccines13060653.
2
Comprehensive immunoinformatics and bioinformatics strategies for designing a multi-epitope based vaccine targeting structural proteins of Nipah virus.用于设计靶向尼帕病毒结构蛋白的多表位疫苗的综合免疫信息学和生物信息学策略。
Front Immunol. 2025 May 13;16:1535322. doi: 10.3389/fimmu.2025.1535322. eCollection 2025.